Treats major depressive disorder (MDD). ANDA 209193, held by Adaptis. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 209193 (Venlafaxine Hydrochloride), held by Adaptis, was first approved by FDA on Oct 31, 2019, with 2 approved supplements and 0 published complete response letters.
Venlafaxine Hydrochloride Extended-Release Tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) Social Anxiety Disorder (SAD) 1.1 Major Depressive Disorder Venlafaxine Hydrochloride Extended-Release Tablets are indicated for the treatment of major depressive disorder (MDD). Efficacy of venlafaxine in MDD was shown in both short-term trials and a longer-term trial in MDD.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2019 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 150MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 225MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Nov 21, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 9, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 31, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters